Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti CCL/CD33 chimeric antigen receptor T cell therapy - Nanjing Legend Biotech

Next Previous
X
Search
Drug Profile

Anti CCL/CD33 chimeric antigen receptor T cell therapy - Nanjing Legend Biotech

Alternative Names: LCAR-AMDR

Latest Information Update: 05 Jan 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nanjing Legend Biotech
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 26 Sep 2023 Institute of Hematology & Blood Diseases Hospital and Nanjing Legend Biotech terminates a phase I trial in Acute myeloid leukemia (In adolescents, In adults, Second-line therapy or greater) in China (Parenteral) due to both the sponsors and collaborator consideration of terminating the study (NCT05654779)
  • 21 Dec 2022 Nanjing Legend Biotech plans a phase I trial for Acute myeloid leukaemia (In children, In adults, Refractory metastatic disease, Second-line therapy or greater) in China (Parenteral) (NCT05654779)
  • 21 Dec 2022 Preclinical trials in Acute myeloid leukaemia (Refractory metastatic disease) in China (Parenteral) (before December 2022) (Nanjing Legend Biotech pipeline, December 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top